Should persons with acute myeloid leukemia (AML) in 1st histological complete remission who are measurable residual disease (MRD) test positive receive an allotransplant?

[1]  N. Potter,et al.  Molecular MRD status and outcome after transplantation in NPM1 mutated AML: results from the UK NCRI AML17 study. , 2019, Blood.

[2]  H. Deeg,et al.  Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  C. Hourigan,et al.  MRD evaluation of AML in clinical practice: are we there yet? , 2019, Hematology. American Society of Hematology. Education Program.

[4]  C. Hourigan,et al.  Statistics and measurable residual disease (MRD) testing: uses and abuses in hematopoietic cell transplantation , 2019, Bone Marrow Transplantation.

[5]  R. Foà,et al.  GIMEMA AML1310 TRIAL OF RISK-ADAPTED, MRD-DIRECTED THERAPY FOR YOUNG ADULTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA. , 2019, Blood.

[6]  H. Dombret,et al.  Peripheral blood minimal/measurable residual disease assessed in flow cytometry in acute myeloblastic leukemia , 2019, Leukemia.

[7]  I. Glauche,et al.  The prognostic potential of monitoring disease dynamics in NPM1-positive acute myeloid leukemia , 2019, Leukemia.

[8]  Michael Stadler,et al.  Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML. , 2018, Blood.

[9]  Markus G. Manz,et al.  Molecular Minimal Residual Disease in Acute Myeloid Leukemia , 2018, The New England journal of medicine.

[10]  Torsten Haferlach,et al.  Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. , 2018, Blood.

[11]  T. Haferlach,et al.  Minimal residual disease (MRD) monitoring and mutational landscape in AML with RUNX1-RUNX1T1: a study on 134 patients , 2018, Leukemia.

[12]  C. Hourigan,et al.  Measurable residual disease testing in acute myeloid leukaemia , 2017, Leukemia.

[13]  M. Voso,et al.  Pre-transplant persistence of minimal residual disease does not contraindicate allogeneic stem cell transplantation for adult patients with acute myeloid leukemia , 2017, Bone Marrow Transplantation.

[14]  Bob Löwenberg,et al.  Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017, Blood.

[15]  B. Wood,et al.  Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis , 2017, Haematologica.

[16]  Inigo Martincorena,et al.  Precision oncology for acute myeloid leukemia using a knowledge bank approach , 2017, Nature Genetics.

[17]  E. Estey,et al.  Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission? , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Yashma Patel,et al.  Assessment of Minimal Residual Disease in Standard-Risk AML. , 2016, The New England journal of medicine.

[19]  E. Vellenga,et al.  Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40–60 years , 2014, Leukemia.

[20]  Bob Löwenberg,et al.  High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Yu Wang,et al.  MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial. , 2013, Blood.

[22]  R. Schlenk,et al.  The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach , 2012, Nature Reviews Clinical Oncology.

[23]  Asha B. Pillai,et al.  Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia. , 2012, Blood.

[24]  F. Lo‐Coco,et al.  Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. , 2012, Blood.

[25]  R. Gale,et al.  Modeling minimal residual disease (MRD)-testing. , 2003, Leukemia research.